Andrew Dickinson
Directeur/Membre du Conseil chez Amryt Pharma Holdings Ltd.
Profil
Andrew Philip Dickinson is currently a Director at Amryt Pharma Holdings Ltd.
starting in 2023.
Prior to this, he was the Chairman at Zymenex A and a Director & Finance Director at Chiesi Ltd.
Postes actifs de Andrew Dickinson
| Sociétés | Poste | Début |
|---|---|---|
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 26/05/2023 |
Anciens postes connus de Andrew Dickinson
| Sociétés | Poste | Fin |
|---|---|---|
Zymenex A/S
 Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Président | - |
Chiesi Ltd.
 Chiesi Ltd. Electronic Equipment/InstrumentsElectronic Technology Chiesi Ltd. develops and markets respiratory products. It offers medicines for the treatment of respiratory disease. The company was founded on June 18, 1987 and is headquartered in Manchester, the United Kingdom. | Directeur Financier/CFO | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Zymenex A/S
Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Health Technology |
Chiesi Ltd.
Chiesi Ltd. Electronic Equipment/InstrumentsElectronic Technology Chiesi Ltd. develops and markets respiratory products. It offers medicines for the treatment of respiratory disease. The company was founded on June 18, 1987 and is headquartered in Manchester, the United Kingdom. | Electronic Technology |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
